INCY241220C75000
- 0.01
- -0.24-96.00%
Incyte Newsroom
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Incyte Analyst Ratings
UBS Initiates Incyte(INCY.US) With Hold Rating, Announces Target Price $77
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte's Mixed Clinical Results and Financial Challenges Lead to Hold Rating
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $86
TD Cowen Remains a Buy on Incyte (INCY)
TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating
Incyte Is Maintained at Sector Perform by RBC Capital